Jaroslav Polák, Martina Hradcová, Jirí Schwarz, Hana Klamová, Petr Stöckbauer, Tomás Kozák, Julius Müller, Cedrik Haskovec
Institute of Hematology and Blood Transfusion, Department of Molecular Genetics, U nemocnice, Prague, Czech Republic.
Leuk Lymphoma. 2005 Nov;46(11):1605-1612. doi: 10.1080/10428190500215100.
Cyclins are very important components of the cell cycle machinery because their levels regulate cell proliferation. They have also been found to be prognostic factors in various cancers. We studied the expression of the positive cell cycle regulators (D cyclins) and the cell proliferation marker (Ki-67) in human acute myeloid (AML), chronic myeloid (CML), acute lymphoblastic (ALL) and chronic lymphocytic (CLL) leukemia [mainly by comparative reverse transcription polymerase chain reaction (RT-PCR)]. Both leukemic and normal cells were positive for cyclin D3 expression. Significant differences were found in the expression of cyclin D1, which was the highest in leukocytes (CD19 + ) of CLL patients whereas lower expression was found in CML, AML and ALL patients and normal bone marrow and peripheral blood leukocytes (P < 0.001). The higher expression of cyclin D1 in leukocytes of CLL patients compared to CML patients was confirmed by quantitative real-time RT-PCR with a TaqMan probe in a subset of CLL and CML patients. Differences in cyclin D1 expression between CLL and CML patients were also confirmed on protein levels by western blotting. Expression of the proliferative marker Ki-67 was high in CML, ALL and AML cells and low in CD19-positive CLL cells. The results demonstrate that the level of cyclin D1 negatively correlates with the proliferation properties of leukemic cells. We did not find any significant relationship between cyclin D1 expression in cells of CML and AML patients and their clinical outcome.
细胞周期蛋白是细胞周期机制的非常重要的组成部分,因为它们的水平调节细胞增殖。它们也被发现是各种癌症的预后因素。我们主要通过比较逆转录聚合酶链反应(RT-PCR)研究了人类急性髓系白血病(AML)、慢性髓系白血病(CML)、急性淋巴细胞白血病(ALL)和慢性淋巴细胞白血病(CLL)中阳性细胞周期调节因子(D型细胞周期蛋白)和细胞增殖标志物(Ki-67)的表达。白血病细胞和正常细胞的细胞周期蛋白D3表达均为阳性。细胞周期蛋白D1的表达存在显著差异,其在CLL患者的白细胞(CD19+)中最高,而在CML、AML和ALL患者以及正常骨髓和外周血白细胞中表达较低(P<0.001)。在一部分CLL和CML患者中,使用TaqMan探针通过定量实时RT-PCR证实了CLL患者白细胞中细胞周期蛋白D1的表达高于CML患者。通过蛋白质印迹法在蛋白质水平上也证实了CLL和CML患者之间细胞周期蛋白D1表达的差异。增殖标志物Ki-67在CML、ALL和AML细胞中表达较高,而在CD19阳性的CLL细胞中表达较低。结果表明,细胞周期蛋白D1的水平与白血病细胞的增殖特性呈负相关。我们未发现CML和AML患者细胞中细胞周期蛋白D1的表达与其临床结局之间存在任何显著关系。